Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2024

23-02-2024 | Original Article

Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method

Authors: Achmad Faturrahman Jundi, M. Dlorifun Naqiyyun, Bisma Barron Patrianesha, Intan A. S. Mu’minah, Ade Riana, Deni Hardiansyah

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2024

Login to get access

Abstract

Purpose

Calculation of the uncertainty of the individual time-integrated activity coefficient (TIACs) is desirable in molecular radiotherapy. However, the calculation of TIAC’s uncertainty in single-time-point (STP) method has never been reported in the literature. This study presents a method based on the Bayesian fitting (BF) to calculate the standard deviation (SD) of individual TIACs in the STP dosimetry.

Methods

Biokinetic data of 177Lu-DOTATATE in kidneys were obtained from PMID33443063. BF methods with extended objective function, which optimize the fitting using prior knowledge of the function’s parameters, were used. Reference TIACs (rTIACs) were calculated by fitting a mono-exponential function to the all-time-point data. The goodness of fit was checked based on the visual inspection and the coefficient of variations (CV) of the fitted parameters < 0.5. BF with relative (BFr) and absolute-based (BFa) variance methods were used to obtain the calculated TIACs (cTIACs) from the STP dosimetry. Performance of the STP method was obtained by calculating the relative deviation (RD) between cTIACs and rTIACs.

Results

Visual inspection showed a good fit for all patients with CV of fitted parameters less than 50%. The mean ± SD of cTIAC’s %RD were 7.0 ± 25.2 for BFr and 2.6 ± 8.9 for BFa. The range of %CV of the individual cTIAC’s SD for BFr and BFa methods was 36–78% and 22–33%, respectively, while the %CV of the rTIAC SD was 0.8–49%.

Conclusion

We introduce the BF method to calculate the SD of individual TIACs in STP dosimetry. The presented method might be used as an alternative method for uncertainty analysis in STP dosimetry.
Appendix
Available only for authorised users
Literature
1.
Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.CrossRefPubMed
2.
Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262–9.CrossRefPubMed
3.
Hardiansyah D, Maass C, Attarwala AA, Müller B, Kletting P, Mottaghy FM, et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2016;43:871–80.CrossRefPubMed
4.
Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177lu-psma-617 therapy using a single posttreatment spect/ct scan: A novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030–8.CrossRefPubMedPubMedCentral
5.
6.
Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT after 177Lu-DOTATATE. J Nucl Med. 2021;62:1118–25.CrossRefPubMedPubMedCentral
7.
Hardiansyah D, Riana A, Beer AJ, Glatting G. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept. EJNMMI Phys. 2023;10:1–12.CrossRef
8.
Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75–81.CrossRefPubMed
9.
Ligonnet T, Pistone D, Auditore L, Italiano A, Amato E, Campennì A, et al. Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept. Phys Medica. 2021;92:75–85.CrossRef
10.
Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45:2456–74.CrossRefPubMedPubMedCentral
11.
Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, et al. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys. 2020;7:63.CrossRefPubMedPubMedCentral
12.
Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177 Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018;5:33.CrossRefPubMedPubMedCentral
13.
Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49:1101–12.CrossRefPubMed
14.
Brosch-Lenz J, Delker A, Völter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767–74.CrossRefPubMedPubMedCentral
15.
Maaß C, Sachs JP, Hardiansyah D, Mottaghy FM, Kletting P, Glatting G. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. EJNMMI Res. 2016;6:1–9.CrossRef
16.
Hardiansyah D, Guo W, Kletting P, Mottaghy FM, Glatting G. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: a simulation study on the effect of sampling schedule and noise. Med Phys. 2016;43:5145–54.CrossRefPubMed
17.
Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, et al. Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy. J Nucl Med. 2016;57:503–8.CrossRefPubMed
18.
Kletting P, Maaß C, Reske S, Beer AJ, Glatting G. Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy. PLoS ONE. 2015;10:1–15.CrossRef
19.
Ardenfors O, Nilsson JN, Thor D, Hindorf C. Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy. EJNMMI Phys. 2022;9:44.CrossRefPubMedPubMedCentral
20.
Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative 177 Lu SPECT/CT with XSPECT quant. J Nucl Med. 2019;60:50–9.CrossRefPubMed
21.
Mirando D, Dewaraja YK, Cole NM, Nelson AS. In pursuit of fully automated dosimetry: evaluation of an automatic VOI propagation algorithm using contour intensity-based SPECT alignments. Eur J Nucl Med Mol Imaging. 2020;In: Eur. J. Nucl. Med. Mol. Imaging. Springer One New York Plaza, Suite 4600, New York, Ny, United States, pp S236–S236.
22.
Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40: 102504.CrossRefPubMed
23.
Bonate PL. Pharmacokinetics pharmacodynamics modeling and simulation, 2nd ed. 2011;Springer, New York.
24.
Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.CrossRefPubMed
25.
Hardiansyah D, Riana A, Kletting P, Zaid NRR, Eiber M, Pawiro SA, et al. A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Phys. 2021;8:82.CrossRefPubMedPubMedCentral
26.
Kletting P, Schimmel S, Hänscheid H, Luster M, Fernández M, Nosske D, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25:264–74.CrossRefPubMed
27.
Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZ-PSMA-617. Nucl Med Mol Imaging. 2010;2021(55):237–44.
28.
29.
Vegt E, De JM, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.CrossRefPubMed
Metadata
Title
Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method
Authors
Achmad Faturrahman Jundi
M. Dlorifun Naqiyyun
Bisma Barron Patrianesha
Intan A. S. Mu’minah
Ade Riana
Deni Hardiansyah
Publication date
23-02-2024
Publisher
Springer Nature Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2024
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00851-8

Other articles of this Issue 3/2024

Nuclear Medicine and Molecular Imaging 3/2024 Go to the issue

Case Report

Annotating the Role of 18F-FDG PET/CT in Fibromatoses: A Benign Masquerader of Malignancies—Is It Really an Advantageous Tool?

Interesting image

Discordant Molecular Imaging Findings with 2-[18F]FDG and [68Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer

Case Report

First Local Experience of Intra-Cavitary Yttrium-90 Citrate Colloid Irradiation via Ommaya Reservoir for Refractory Cystic Craniopharyngioma: a Case Report

Interesting image

Hepatic Superscan in Medullary Thyroid Carcinoma: A Rare Presentation in [18F]FDG PET/CT

Original Article

Incidentally Detected Gallbladder Carcinoma: Can F-18 FDG PET/CT Aid in Staging and Prognostication?

Letter to editor

Contribution of ChatGPT in Parkinson’s Disease Detection